09.30-10.45 am **Curtain Raiser - What was new this year?**

- Exercise-Induced Cardiac Troponin I - PP Mohanan
- Polypill for Cardiovascular Disease Prevention in an Underserved Population - K Venugopal
- Year in Hypertension - B Williams

10.45-12.15 pm **Atrial Fibrillation**

- Long term complications of A fib - U Pandurangi
- Post operative A Fib : Is it benign? - B Gersh
- Which NOAC for which patient? - A Bhagwat
- Emerging indications for RF ablation - A Vora
- Discussion

12.00-1.15 pm **Rethinking current treatment strategies of BP Management**

- Home BP monitoring - T Nair
- Round the clock control of BP - NV Deshpande
- Is sodium restriction effective for lowering blood pressure? - U Jadhav
- New NICE guidelines : a realistic compromise? - B Williams
- Discussion

1.30-2.15 pm **Lunch**

2.15-3.45 pm **Combination therapy - A trend set in India**

- How wider use of combinations will improve control of the main cardiovascular risk factors - R Gupta
- Therapeutic Adherence- mainstay in reaching BP goal - JJ Dalal
- Triple drug antihypertensive SPCs: the logical choice for Indian scenario - S Ray
- Discussion
### Cardiology, Kidney & Diabetes (CKD)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.45-5.00pm</td>
<td><strong>Introduction</strong>&lt;br&gt;<strong>The benefits of GLP1RAs and SGLT2i on CV outcomes:</strong>&lt;br&gt;how similar? how different? - S Del Prato</td>
</tr>
<tr>
<td>5.00-5.30pm</td>
<td>Break</td>
</tr>
<tr>
<td>5.30-6.45pm</td>
<td><strong>Panchayat - Off patent Ticagrelor, a turning point in management of ACS?</strong>&lt;br&gt;Plaque to thrombosis to ACS - R Mathew&lt;br&gt;P2Y12 inhibitors: How they are different - G Koshy&lt;br&gt;DAPT up-to-date - MS Hiremath&lt;br&gt;ACSnomics - HM Mardikar&lt;br&gt;Discussion</td>
</tr>
<tr>
<td>6.45-8.00pm</td>
<td><strong>Panchayat - Lipid Management</strong>&lt;br&gt;Introduction&lt;br&gt;Is it right time to screen for high LPA? - S Ray&lt;br&gt;Hypertriglyceridemia: How to diagnose &amp; how to treat? - S Kale&lt;br&gt;High dose statins in the era of PCSK9 inhibitors – JJ Dalal&lt;br&gt;Discussion</td>
</tr>
</tbody>
</table>

### Curtain Raiser - What was new this year?

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.30-10.45am</td>
<td><strong>Introduction</strong>&lt;br&gt;Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial - A Nigam&lt;br&gt;Calorie restriction and cardiometabolic risk (CALERIE) - U.Ayyagari&lt;br&gt;Age at diagnosis &amp; CV disease - S Kale&lt;br&gt;Discussion</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>10.45-12.15pm</td>
<td><strong>Personalised medicine - for CV Disease in young diabetics</strong></td>
</tr>
<tr>
<td></td>
<td>15+3min • Calcium score &amp; CT Angio - N Desai</td>
</tr>
<tr>
<td></td>
<td>15+3min • Aspirin, statin or both? - SS Iyengar</td>
</tr>
<tr>
<td></td>
<td>20min • Oral combination therapy in early stage - P Gaede</td>
</tr>
<tr>
<td></td>
<td>• Panel Discussion</td>
</tr>
<tr>
<td></td>
<td>• Q &amp; A</td>
</tr>
<tr>
<td>12.15-1.30pm</td>
<td><strong>Reducing hypoglycaemia in patients treated with insulin</strong></td>
</tr>
<tr>
<td></td>
<td>18min • Impact of hypoglycaemia - M Fisher</td>
</tr>
<tr>
<td></td>
<td>18min • Impact of impaired renal function - S. Shah</td>
</tr>
<tr>
<td></td>
<td>18min • Impact of addition of SGLT2 inhibitors - S Del Prato</td>
</tr>
<tr>
<td></td>
<td>20min • Discussion</td>
</tr>
<tr>
<td>1.30-2.15pm</td>
<td>Lunch</td>
</tr>
<tr>
<td>2.15-3.45pm</td>
<td><strong>Drugs for the Heart in Diabetes Session I</strong></td>
</tr>
<tr>
<td></td>
<td>18+4min • Will paradigm shift away from SU's? - A.K. Das</td>
</tr>
<tr>
<td></td>
<td>18+4min • Alpha Glucosidase Inhibitors &amp; Heart - S Shaikh</td>
</tr>
<tr>
<td></td>
<td>18+4min • Have DPP4 inhibitors come to a dead end? - M Chadha</td>
</tr>
<tr>
<td></td>
<td>18+4min • T2DM Management Beyond HbA1c: The Vasculo-Metabolic Axis &amp; Place of SGLT2-inhibitors - P Sanzgiri</td>
</tr>
<tr>
<td>3.45-5.00pm</td>
<td><strong>Drugs for the Heart in Diabetes Session II</strong></td>
</tr>
<tr>
<td></td>
<td>18+4min • The right glucose-lowering drugs for the right patient - A.K. Das</td>
</tr>
<tr>
<td></td>
<td>18+4min • Glycemic Control and CV Outcome: Twin Aspects-DPP4i + SGLT2i FDC - M John</td>
</tr>
<tr>
<td></td>
<td>18+4min • Revisiting STENO &amp; CV risk reduction with newer glucose lowering drugs - P Gaede</td>
</tr>
<tr>
<td></td>
<td>• Discussion</td>
</tr>
<tr>
<td>5.00-5.30pm</td>
<td>Break</td>
</tr>
<tr>
<td>5.30-6.45pm</td>
<td><strong>EACD Classroom - Session I</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Personalised medication in type 2 DM</strong></td>
</tr>
<tr>
<td></td>
<td>25min • The Era of Precision medicine in diabetes - S Del Prato</td>
</tr>
<tr>
<td></td>
<td>25min • Personalised treatment of HF - J McMurray</td>
</tr>
<tr>
<td></td>
<td>• Discussion</td>
</tr>
</tbody>
</table>
2.15-3.45pm **ECG Masterclass**
- B Gersh, U Pandurangi & A Vora

3.45-5.00pm **ECG Quiz**
- ECG 1 - M.S. VISNUDAS
- ECG 2 - Akshay Bafna
- IECG 3 - Vikas Singh
- ECG 4 - Nilesh Banthia
- ECG 5 - S N Panda
- ECG 6 - Seba Mathew

5.00-5.30pm **Break**

5.30-6.45pm **Discuss with the Expert on the spot I**
- 25min • When should we stop Aspirin in elderly?
  • Dr NV Deshpande with Dr Jamshed Dalal
- 25min • ARNI in uncontrolled HT
  • Dr A Bhagwat with Prof B Williams
- 25min • PCSK9 inhibitors
  • Dr PP Mohanan with Dr SS Iyengar

6.45-8.00pm **Discuss with the Expert on the spot II**
- 25min • Cardiovascular consequences of sleep apnea
  • Dr NV Deshpande with Prof Bernard Gersh
- 25min • Selecting SGLT2 inhibitors based on patient profile
  • Dr A Nigam with Prof Stefano Del Prato
- 25min • ARNI in HF
  • Dr A Dhall with Prof J McMurray

**EACD Classroom - Session II**

**New Insights**
- 20min • Do we need lower BP targets for diabetics? - B Williams
- 20min • Circulating liver enzymes & Diabetes - E Ferrannini
  • Discussion

**8th NOV, FRIDAY**

**DAY I**

**ECO-Hall**

**6.45-8.00pm**

- **Do we need lower BP targets for diabetics?**
  - B Williams

- **Circulating liver enzymes & Diabetes**
  - E Ferrannini
## Gaps in Knowledge - AMI

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 9.00-10.15am | Lytic therapy when PCI centre in nearby - R Mathew  
|           | Beta blockers in post AMI management - A Banerjee  
|           | Cardiogenic Shock - A Dhall  
|           | AICD indications - do we need to revisit in era of ARNI & SGLT2i - U Pandurangi  
|           | Discussion                    |

## Adda Break

- Remogliflozin - SGLT2 inhibitor for common man - S Kale, M John

## Guest Lectures

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10.15-10.45am | Insulin resistance - E Ferrannini  
|           | Understanding nuances in management of HT : Protecting Hearts and Minds - B Williams  
|           | New guidelines in DM - S Del Prato           |

## Guest Lectures

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12.00-1.15pm | Treating patients with HFpEF : What progress are we making? - J McMurray  
|           | Diabetes prevention and early treatment - S Del Prato  
|           | Cardiovascular consequences of sleep apnea and what can we do about it? - B Gersh |

## Lunch

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 1.15-2.00pm | SGLT2 inhibitors, CREDENCE & Peep into future - E Ferrannini  
|           | CREDENCE - A Nephrologists view - A Kirpalani  
|           | Discussion                    |

## Opportunities to optimise management of HF

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 3.15-4.30pm | Walk-in patient with stable HF patient - B Pinto  
|           | Patient of decompensated HF at discharge - J McMurray  
|           | Panel Discussion & audience interaction          |
4.30-5.15pm  **Adda Break**

- Statins & Ezitimibe combination is back!
- Discussant - JJ Dalal, NV Deshpande, U Jadhav

5.15-6.30pm  **Panchayat - Blood Pressure in a 100-Year Perspective**

20min  - Understanding Hypertension - E Ferrannini
20min  - How did we arrive at proper targets? - T Nair
20min  - Redefining diuretics use in hypertension: why select a thiazide-like diuretic? - B Williams
- Discussion

6.30-7.00pm  **Award Ceremony**

15min  - Legends Talk
- Legend of Diabetes Award

7.00pm  **Champagne Reception**
7.30pm  **Dinner**

---

**DAY II  9TH NOV, SATURDAY  HALL II**

8.00-9.00am  **Breakfast Session - Mini-Debates**

- Treating Obesity & Diabetes - Start with metformin & SGLT2 i combination
  12min  - Pro - S Kota
  12min  - Con - S Shah
  6min  - Discussion
  - Treating BP Control - Drug Matters
  12min  - Pro - K Venugopala
  12min  - Con - T Nair
  6min  - Discussion

9.00-10.15am  **Gaps in Knowledge - CardioDiabetes**

12+6min  - Efficacy and safety of SGLT2 inhibitors in elderly - M Fisher
12+6min  - Nocturnal hypertension in diabetes - JJ Dalal
12+6min  - Who should be the Leader? Diabetologist, Nephrologist or Cardiologist? - A Kirpalani
12+6min  - Aspirin for primary prevention in Diabetes - JS Bhuvaneswari
15min  - Discussion

10.15-10.45am  **Break**
10.45-12.00noon  ➤ Debate & Discuss

- Should HbA1c still be the main target for diabetes treatment?
  15min  •  Pro - U Ayyagari
  15min  •  Con - P Gaede
  3min  •  Rebuttal I
  3min  •  Rebuttal II
  10min  •  Discussion
  18min  •  Controversies about HbA1c targets - Gananpathi
  10min  •  Discussion

12.00-1.15pm  ➤ Targets.....Targets.....Targets.....

- Blood pressure target to <120 /<70 mmHg associates with poor outcome
  15min  •  Pro - A Bhagwat
  15min  •  Con - PP Mohanan
  3min  •  Rebuttal I
  3min  •  Rebuttal II
  10min  •  Discussion
  18min  •  HT Management - Identifying right patient & right target
    - B Williams
  10min  •  Discussion

1.15-2.00pm  ➤ Lunch

2.00-3.15pm  ➤ Insulin Symposium

  15min  •  Moving from Orals to Injectables....Why,When & How?
    - A Nigam”
  15min  •  Choosing basal insulin over SGLT2 inhibitors - P Gaede
  15min  •  BE-SMART: Basal Early Strategies to Maximize A1C Reduction
    with Oral Therapy - V Negalur
  15min  •  Dissecting head to head data of newer generation basal insulin - AG Unnikrishnan
  15min  •  Discussion

3.15-4.30pm  ➤ The real science behind what we eat!

  18min  •  Gut response to food - E Ferrannini
  15min  •  Intermittent fasting - R Adlyne
  18min  •  Scientific evidence of diet in cardio-metabolic health - Rajiv Gupta
  20min  •  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.30-5.15pm</td>
<td>Break</td>
</tr>
<tr>
<td>5.15-6.30pm</td>
<td><strong>Open Mike symposium</strong></td>
</tr>
<tr>
<td></td>
<td>8 slides + 10mins Can diet fads increase CV risk? - NV Deshpande</td>
</tr>
<tr>
<td></td>
<td>8 slides + 10mins Reducing obesity with antidiabetics - S Shaikh</td>
</tr>
<tr>
<td></td>
<td>8 slides + 10mins Postprandial hyperglycemia - A Nigam</td>
</tr>
<tr>
<td></td>
<td>8 slides + 10mins Pioglitazone in clinical practice - M John</td>
</tr>
<tr>
<td>6.30-7.00pm</td>
<td><strong>Award Ceremony</strong></td>
</tr>
<tr>
<td></td>
<td>15min Legends Talk</td>
</tr>
<tr>
<td></td>
<td>Legend of Diabetes Award</td>
</tr>
<tr>
<td>7.00pm</td>
<td>Champagne Reception</td>
</tr>
<tr>
<td>7.30pm</td>
<td>Dinner</td>
</tr>
</tbody>
</table>

**DAY II 9TH NOV, SATURDAY HALL III**

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00-10.15am</td>
<td><strong>Digital apps for diabetes treatment and prevention: opportunities and challenges</strong></td>
</tr>
<tr>
<td></td>
<td>Doctor and patient perspective</td>
</tr>
<tr>
<td></td>
<td>Diabetes educator perspective</td>
</tr>
<tr>
<td></td>
<td>Revenue model for the doctor</td>
</tr>
<tr>
<td></td>
<td>Revenue for the industry</td>
</tr>
<tr>
<td></td>
<td>(Moderators to discuss. No speakers)</td>
</tr>
<tr>
<td>10.15-10.45am</td>
<td>Break</td>
</tr>
<tr>
<td>10.45-12.00pm</td>
<td><strong>Contentious issues in management of Young Diabetics (&lt;40yrs)</strong></td>
</tr>
<tr>
<td></td>
<td>12+6min Dealing with atypical diabetes in India - Ganapathi</td>
</tr>
<tr>
<td></td>
<td>12+6min Should we start insulin early? - R Adlyne</td>
</tr>
<tr>
<td></td>
<td>12+6min Should everybody receive Aspirin &amp; Statin? - A Banerjee</td>
</tr>
<tr>
<td></td>
<td>12+6min Are DPP4 inhibitors still second line therapy after Metformin? - M Fisher</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
</tr>
</tbody>
</table>
1.15-2.00pm Lunch

2.00-3.15pm **Contentious issues - Management of HF**
- 12+6min "Prevention of Heart Failure in Diabetes: Role of Antihypertensive Therapy - A Pareek"
- 12+6min IV decongestion therapy in-hospital - K Sharma
- 12+6min Mineralocorticoid receptor antagonists - GL Sharma
- 12+6min How to prevent hyponatremia? - S Banerjee

3.15-4.30pm **So called Vices - Advising patients based on science**
- 15min The Chocolates - Shilpa Joshi
- 15min The red wine - S Kale
- 15min Alcohol - S Ray
- 30min Discussion

**DAY II**

**9TH NOV, SATURDAY**

**EACD Classroom**

9.00-10.00am **EACD Classroom - Session III**
- Pregnancy & Diabetes - Moderators: S. Kale, S. Shaikh
- Case Based Discussions

10.00-10.45am **EACD Classroom - Session IV**
- Thyroid Disorders - Moderators: S. Shah, M. John
- Case Based Discussions

4.30-5.15pm **EACD Classroom - Session V**
- Managing type 1 DM - Important aspects - Moderators: A Nigam, M. John
- Case Based Discussions
8.15-9.15am | Breakfast session - Living Longer Living Better

- The Secret to Good Health: 10,000 Steps, fitbit & the science
  - T Nair
- Artificial intelligence, Retina & CVD - HM Mardikar
- Assessment of myocardial viability: In whom, how and why?
  - A Bhagwat

9.15-10.45am | Prioritizing injectable therapies in diabetes

- GLP1RAs: From anti-diabetic to cardiometabolic drug
  - M Nauck
- CV safety with basal insulins - Uday Phadke
- Tackling Post Prandial Peaks and Outcomes - S. Kale
- Achieving Glycemic Goals: Indian reality - Prasoon Deb
- Discussion

10.45-12.15pm | EASD Highlights

- Comparing metformin vs metformin plus Vildagliptin
  - the VERIFY trial - P Gaede
- Comparing degludec vs U200 glargine
  - the CONCLUDE trial - P Gaede
- Comparing semaglutide vs canagliflozin
  - the SUSTAIN 8 trial - M Fisher
- CV outcomes with linaglitin vs glimepiride - the CAROLINA trial
  - M Fisher
- Discussion

12.15-1.30pm | Futuristic view of cardio-diabetes management

- Introduction
- Incretin-based therapies: where will we be 50 years from now?
  - M Nauck
- What Does the Future Hold? - E Ferrannini
- Discussion
- Lunch
9.15-10.45am  **Guest Lectures**

25+5min • The need for new trials of old drugs: ACEi/ARB and beta blockers in post MI patients - B Gersh  
25+5min • How to assess heart failure with preserved ejection fraction? - J Bax  
25+5min • (Dr Reddy’s)The very high risk CVD-role of PCSK9 inhibitors - JJ Dalal  
  • Discussion

10.45-12.15pm  **Stroke for Physicians**

25+5min • Acute stroke : Time is brain - S Hastak  
15+5min • Control of BP in stoke - S Bansal  
15+5min • Algorithm Based Management with Dabigatran - G Koshy  
15min • Discussion

12.15-1.30pm  **Clinical Scenarios**

12+6min • Calcium score & CT coronary angio in high risk patients - MS Hiremath  
12+6min • What Physicians should know about FFR? - R Mathew  
12+6min • Heart rate reduction - S Sathe  
12+6min • Type A Avortic dissection : a tough call - S Banerjee  
  • Discussion

1.00pm  Lunch
## Session I
### Introduction
- Course Directors: M Fisher, P Gaede

### Discussion
- Insulin management for type 1 and type 2 diabetes - P Gaede

### Closing Remarks

### Workshop I
- Glycaemic management to reduce micro and macro-vascular disease - M Fisher
- Discussion

### Lunch

### Workshop II
- Insulin management for type 1 and type 2 diabetes

### Session II
- Introduction
  - Multi-risk factor interventions - Steno 2 and beyond - P Gaede
  - Discussion
  - Future prospects for glycaemia, lipids and blood pressure management - M Fisher
  - Discussion
  - Closing Remarks

### Certification & Photograph